Detalhe da pesquisa
1.
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer.
N Engl J Med
; 379(20): 1926-1936, 2018 Nov 15.
Artigo
Inglês
| MEDLINE | ID: mdl-30345905
2.
Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies.
Breast Cancer Res
; 22(1): 27, 2020 03 12.
Artigo
Inglês
| MEDLINE | ID: mdl-32164785
3.
A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients.
Br J Cancer
; 120(5): 475-480, 2019 03.
Artigo
Inglês
| MEDLINE | ID: mdl-30745582
4.
Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2 + metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16).
Br J Cancer
; 121(12): 985-990, 2019 12.
Artigo
Inglês
| MEDLINE | ID: mdl-31690831
5.
Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.
N Engl J Med
; 373(3): 209-19, 2015 Jul 16.
Artigo
Inglês
| MEDLINE | ID: mdl-26030518
6.
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.
N Engl J Med
; 372(8): 724-34, 2015 Feb 19.
Artigo
Inglês
| MEDLINE | ID: mdl-25693012
7.
Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results.
Oncologist
; 22(9): 1028-1038, 2017 09.
Artigo
Inglês
| MEDLINE | ID: mdl-28652278
8.
A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer.
Breast Cancer Res Treat
; 165(3): 601-609, 2017 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-28681171
9.
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.
Lancet Oncol
; 17(4): 425-439, 2016 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-26947331
10.
Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial.
Lancet Oncol
; 17(3): 357-366, 2016 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-26822398
11.
Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3).
Oncologist
; 21(10): 1165-1175, 2016 10.
Artigo
Inglês
| MEDLINE | ID: mdl-27368881
12.
The role of the addition of ovarian suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or regain menstruation after chemotherapy (ASTRRA): study protocol for a randomized controlled trial and progress.
BMC Cancer
; 16: 319, 2016 05 19.
Artigo
Inglês
| MEDLINE | ID: mdl-27197523
13.
Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial.
Lancet Oncol
; 16(16): 1700-10, 2015 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-26596672
14.
Quality of life (QoL) in metastatic breast cancer patients with maintenance paclitaxel plus gemcitabine (PG) chemotherapy: results from phase III, multicenter, randomized trial of maintenance chemotherapy versus observation (KCSG-BR07-02).
Breast Cancer Res Treat
; 152(1): 77-85, 2015 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-26033708
15.
The Value of Ki67 in Very Young Women with Hormone Receptor-Positive Breast Cancer: Retrospective Analysis of 9,321 Korean Women.
Ann Surg Oncol
; 22(11): 3481-8, 2015 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-25652052
16.
Ventriculolumbar perfusion chemotherapy with methotrexate for treating leptomeningeal carcinomatosis: a Phase II Study.
Oncologist
; 19(10): 1044-5, 2014 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-25209375
17.
Treatment factors affecting breast cancer-related lymphedema after systemic chemotherapy and radiotherapy in stage II/III breast cancer patients.
Breast Cancer Res Treat
; 148(1): 91-8, 2014 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-25253173
18.
High volumetric breast density predicts risk for breast cancer in postmenopausal, but not premenopausal, Korean Women.
Ann Surg Oncol
; 21(13): 4124-32, 2014 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-24934582
19.
Comparison of sentinel lymph node biopsy guided by the multimodal method of indocyanine green fluorescence, radioisotope, and blue dye versus the radioisotope method in breast cancer: a randomized controlled trial.
Ann Surg Oncol
; 21(4): 1254-9, 2014 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-24356798
20.
Combination of docetaxel and TSU-68, an oral antiangiogenic agent, in patients with metastatic breast cancer previously treated with anthracycline: randomized phase II multicenter trial.
Invest New Drugs
; 32(4): 753-61, 2014 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-24715580